Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis

Authors

  • Michal Solomon Michal Solomon, Department of Dermatology, The Chaim Sheba Medical Center, IL-52621 Tel Hashomer, Israel
  • Shoshana Greenberger
  • Maya Milner
  • Felix Pavlotzky
  • Aviv Barzilai
  • Eli Schwartz
  • Noa Hadayer
  • Sharon Baum

DOI:

https://doi.org/10.2340/actadv.v102.2079

Keywords:

Leishmania tropica, liposomal amphotericin B, L-AmB, sodium stibogluconate, cutaneous leishmaniasis, systemic treatment

Abstract

The effectiveness of systemic treatment for Leishmania tropica cutaneous leishmaniasis remains unclear. The purpose of the study is to evaluate the efficacy and safety of systemic treatments for L. tropica cutaneous leishmaniasis. This retrospective study was performed in 114 patients. Systemic treatments included liposomal amphotericin B and sodium stibogluconate. All patients underwent systemic treatment for L. tropica cutaneous leishmaniasis. Favourable treatment responses were recorded in 72.5% and 70.2% of the patients in the liposomal amphotericin B and sodium stibogluconate groups, respectively; 25.3% and 46% of those in the liposomal amphotericin B and sodium stibogluconate groups respectively, experienced at least one adverse effect. Lesions in cartilaginous areas were associated with higher treatment failure. Prior topical or systemic treatment increased the chance of future systemic treatment success. Liposomal amphotericin B was associated with a shorter intravenous treatment duration and better safety profile. Thus, liposomal amphotericin B is the treatment of choice for L. tropica cutaneous leishmaniasis.

Downloads

Download data is not yet available.

References

Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012; 7: e35671.

https://doi.org/10.1371/journal.pone.0035671

Pigott DM, Golding N, Messina JP, Battle KE, Duda KA, Balard Y, et al. Global database of leishmaniasis occurrence locations, 1960-2012. Sci Data 2014; 1: 140036.

https://doi.org/10.1038/sdata.2014.36

Jaffe CL, Baneth G, Abdeen ZA, Schlein Y, Warburg A. Leishmaniasis in Israel and the Palestinian Authority. Trends Parasitol 2004; 20: 328-332.

https://doi.org/10.1016/j.pt.2004.05.001

Schlein Y, Warburg A, Schnur LF, Le Blancq SM, Gunders AE. Leishmaniasis in Israel: reservoir hosts, sandfly vectors and leishmanial strains in the Negev, Central Arava and along the Dead Sea. Trans R Soc Trop Med Hyg 1984; 78: 480-484.

https://doi.org/10.1016/0035-9203(84)90067-1

Jacobson RL, Eisenberger CL, Svobodova M, Baneth G, Sztern J, Carvalho J, et al. Outbreak of cutaneous leishmaniasis in northern Israel. J Infect Dis 2003; 188: 1065-1073.

https://doi.org/10.1086/378204

Hepburn NC. Cutaneous leishmaniasis. Clin Exp Dermatol 2000; 25: 363-370.

https://doi.org/10.1046/j.1365-2230.2000.00664.x

Klaus S, Frankenburg S. Cutaneous leishmaniasis in the Middle East. Clin Dermatol 1999; 17: 137-141; discussion 105-136.

https://doi.org/10.1016/S0738-081X(99)00006-1

Momeni AZ, Aminjavaheri M. Treatment of recurrent cutaneous leishmaniasis. Int J Dermatol 1995; 34: 129-133.

https://doi.org/10.1111/j.1365-4362.1995.tb03598.x

Moskowitz PF, Kurban AK. Treatment of cutaneous leishmaniasis: retrospectives and advances for the 21st century. Clin Dermatol 1999; 17: 305-315.

https://doi.org/10.1016/S0738-081X(99)00049-8

Magill AJ, Grögl M, Gasser RA, Jr, Sun W, Oster CN. Visceral infection caused by leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328: 1383-1387.

https://doi.org/10.1056/NEJM199305133281904

Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63: e202-e264.

https://doi.org/10.1093/cid/ciw670

Heras-Mosteiro J, Monge-Maillo B, Pinart M, Lopez Pereira P, Reveiz L, Garcia-Carrasco E, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2017; 12: CD005067.

https://doi.org/10.1002/14651858.CD005067.pub5

Solomon M, Schwartz E, Pavlotsky F, Sakka N, Barzilai A, Greenberger S. Leishmania tropica in children: a retrospective study. J Am Acad Dermatol 2014; 71: 271-277.

https://doi.org/10.1016/j.jaad.2013.12.047

Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296-306.

https://doi.org/10.4269/ajtmh.1992.46.296

Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011; 25: 973-977.

https://doi.org/10.1111/j.1468-3083.2010.03908.x

Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83: 1028-1033.

https://doi.org/10.4269/ajtmh.2010.10-0171

Kamink S, Masih B, Ali N, Ullah A, Khan SJ, Ashraf S, et al. Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy-A retrospective analysis. PLoS Negl Trop Dis 2021; 15: e0008988.

https://doi.org/10.1371/journal.pntd.0008988

Monroy-Ostria A, Nasereddin A, Monteon VM, Guzmán-Bracho C, Jaffe CL. ITS1 PCR-RFLP diagnosis and characterization of leishmania in clinical samples and strains from cases of human cutaneous leishmaniasis in States of the Mexican Southeast. Interdiscip Perspect Infect Dis 2014; 2014: 607287.

https://doi.org/10.1155/2014/607287

Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, Lopez-Velez R, Garcia-Hernandez R, et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis 2017; 11: e0006052.

https://doi.org/10.1371/journal.pntd.0006052

Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3: e162.

https://doi.org/10.1371/journal.pmed.0030162

Karamian M, Bojd MS, Salehabadi A, Hemmati M, Barati DA. Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. East Mediterr Health J 2015; 21: 280-286.

https://doi.org/10.26719/2015.21.4.280

Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother 2012; 56: 1031-1041.

https://doi.org/10.1128/AAC.00030-11

Mwenechanya R, Kovářová J, Dickens NJ, Mudaliar M, Herzyk P, Vincent IM, et al. Sterol 14α-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana. PLoS Negl Trop Dis 2017; 11: e0005649.

https://doi.org/10.1371/journal.pntd.0005649

Ollech A, Solomon M, Horev A, Reiss-Huss S, Ben-Amitai D, Zvulunov A, et al. Cutaneous leishmaniasis treated with miltefosine: a case series of 10 paediatric patients. Acta Derm Venereol 2020; 100: adv00322.

https://doi.org/10.2340/00015555-3669

Downloads

Published

2022-05-24

How to Cite

Solomon, M., Greenberger, S., Milner, M., Pavlotzky, F., Barzilai, A., Schwartz, E., Hadayer, N., & Baum, S. (2022). Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis. Acta Dermato-Venereologica, 102, adv00721. https://doi.org/10.2340/actadv.v102.2079